Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | BGB-283 |
Trade Name | |
Synonyms | Lifirafenib |
Drug Descriptions |
Lifirafenib (BGB-283) is a dual RAF kinase and EGFR inhibitor, which may lead to decreased tumor cell proliferation and reduced growth of tumors with activation of BRAF and/or EGFR (PMID: 26208524, PMID: 32182156). |
DrugClasses | BRAF Inhibitor 21 EGFR Inhibitor (Pan) 55 |
CAS Registry Number | 1446090-79-4 |
NCIT ID | C124995 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BGB-283 | BGB-283 | 10 | 1 |
BGB-283 + Cetuximab | BGB-283 Cetuximab | 1 | 0 |
BGB-283 + MK-8353 | BGB-283 MK-8353 | 2 | 0 |
BGB-283 + PD-0325901 | BGB-283 PD-0325901 | 1 | 1 |
BGB-283 + Pimasertib | BGB-283 Pimasertib | 1 | 0 |
BGB-283 + SCH772984 | BGB-283 SCH772984 | 3 | 0 |
BGB-283 + Selumetinib | BGB-283 Selumetinib | 0 | 0 |
BGB-283 + Trametinib | BGB-283 Trametinib | 4 | 0 |
BGB-283 + Ulixertinib | BGB-283 Ulixertinib | 2 | 0 |
BGB-283 + Vemurafenib | BGB-283 Vemurafenib | 2 | 0 |